Inve India ▾

Neuland Laboratories share price & results

Neuland Laboratories Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Hyderabad API maker & CDMO with 3 US FDA-audited plants, 100+ APIs, serving 80+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue642 ₹ crore+119.1% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin35.0 %+23.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit147 ₹ crore+950.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity29.35 %+8.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-2.42 %−10.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)78.35 %+42.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

6 of 9 judged targets kept · 7 open · verdicts reflect calls analysed to Q1 FY27.

Neuland Laboratories Limited management guidance track record on Inve: 16 targets tracked across analysed earnings calls (6 achieved, 3 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
Inventory Days~90 days in next 3 quarters
Call transcript, Q3 FY26 · 9 Feb 2026		Q3 FY26Q1 FY27:Working capital days improved significantly to 84 days, meeting the target of ~90 days within the specified timeframe.
Call transcript, Q1 FY27 · 5 Aug 2026		Achieved
Peptide DMF Filings2 DMFs (Tirzepatide, Difelikefalin)
Call transcript, Q3 FY25 · 11 Feb 2025		Q3 FY25Q1 FY27:No specific mention of the Tirzepatide or Difelikefalin DMF filings, though management confirmed 'multiple projects lined up at various stages' for the new peptide facility.
Call transcript, Q1 FY27 · 5 Aug 2026		Ghosted
Long-term EBITDA Margin~30%
Call transcript, Q3 FY26 · 9 Feb 2026		Q3 FY26Q1 FY27:Management revised the long-term target downwards to '25% plus', a dilution from the original aspiration of ~30%. 'in terms of our plans, in terms of our long term, 25% plus is what we would be coming for.'
Call transcript, Q1 FY27 · 5 Aug 2026		Revised Down

Source: Inve Guidance Tracker for Neuland Laboratories Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Neuland Laboratories Limited's 16 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 13 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹19,055 +1.01% · +₹190

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance +18.4% 1Y

₹15k₹20kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 7 Nov 2025Q3 FY26 — 9 Feb 2026Q4 FY26 — 12 May 2026Q1 FY27 — 5 Aug 2026

1Y: ₹16,088 on 24 Oct 2025 → ₹19,055. High ₹23,995 (8 Sept 2026), low ₹11,555 (23 Mar 2026).

Previous close
₹18,865
Market cap
₹24.4k Cr
52-week range
₹11,555 – ₹23,995
One year
+20.62%
Price to earnings (TTM to Jun 2026)
48.99×
Return on equity (TTM to Jun 2026)
29.35%

Overview

Symbol
NSE:NEULANDLAB
Exchange
NSE
Currency
INR

What Neuland Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Neuland Laboratories manufactures Active Pharmaceutical Ingredients (APIs) and provides contract development and manufacturing (CDMO) services to global pharmaceutical and biotech companies. It operates through two segments: Generic APIs (GDS), which supplies over 100 developed APIs across 10 therapeutic areas to a worldwide customer base, and CDMO Services (CMS), which undertakes process development, IND/NDA filing support and cGMP manufacturing of RSMs/KSMs, intermediates and APIs for innovator clients' clinical and commercial programs, including peptide-based molecules. Manufacturing is carried out at three US FDA and cGMP-compliant facilities in Hyderabad with a combined reactor volume of about 12,26,000 litres, backed by a dedicated chemical, analytical and peptide R&D centre. Exports form the bulk of the business, with customers spread across more than 80 countries.

Segments

  • Generic APIs (GDS)
  • CDMO Services (CMS)
Manufacturing facilities
3 US FDA & cGMP-compliant units in Hyderabad (Unit I, II, III)
Total reactor volume
12,26,000 litres
Countries served
80+
APIs developed
100+ APIs across 10 therapeutic areas
DMFs filed worldwide
1,007+
Active US DMFs
75
Founded 1984Headquarters Hyderabad, IndiaEmployees 2,188 (FY2026) Company website

How the price took the results

close before → close after

Q1 FY27
+3.5%
5 Aug
Q4 FY26
−3.7%
12 May
Q3 FY26
+6.6%
9 Feb
Q2 FY26
+1.6%
7 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Neuland Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow Neuland Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Neuland Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.